Cancer Diagnostics Segmentation
The market is segmented by product into platform based products and instruments, out of which, the instrument segment is anticipated to grow at the highest rate in the cancer diagnostics market on account of rising cancer cases, growing geriatric population, technological advancements and increasing sedentary lifestyle.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Application |
|
|
By End User |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of cancer diagnostics is estimated at USD 119.89 billion.
Cancer Diagnostics Market size was over USD 113.89 billion in 2024 and is poised to exceed USD 248.95 billion by 2037, growing at over 6.2% CAGR during the forecast period i.e., between 2025-2037.
North America industry is anticipated to account for largest revenue share by 2037, backed by increasing geriatric population, rising research and development initiatives by the government, increasing cancer cases among the population and need for evidence based treatment for cancer.
The major players in the market are Siemens Healthcare Gmbh, GE Healthcare, Abbott, Becton, Dickinson & Company, Illumina Inc., Hologic Inc., F.Hoffman-La Roche, Qiagen NV, Phillips Healthcare, CR Bard Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., Biocartis SA, Biocare Medical LLC, Cancer Genetics Inc., Myriad Genetics, and others.
